Enterprise Value

854.7M

Cash

82.25M

Avg Qtr Burn

-33.87M

Short % of Float

10.83%

Insider Ownership

0.45%

Institutional Own.

39.06%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Nexletol (bempedoic acid) Details
Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia

Approved

Quarterly sales

Nexlizet (bempedoic acid and ezetimibe) Details
Hypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction

Approved

Quarterly sales